Day: May 11, 2020

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).Dear Shareholders,In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. without the physical presence of the shareholders.The VoteUnder these conditions, shareholders are invited to vote remotely, prior to the General Meeting, by giving a proxy to the Chairman or by returning the voting form.Exceptionally, we invite not to give a proxy to a third party to represent you at the meeting insofar as the meeting will be held without the physical presence of the shareholders and therefore of any third party...

AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2020. As of March 31, 2020, MTEM’s cash and investments totaled $108 million, which is expected to fund operations into 2022.“We continue to make meaningful progress at MTEM despite the headwinds that COVID-19 has created for clinical trial site initiation and patient enrollment,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive Officer and Scientific Officer. “We expect to report interim clinical data this year from our three MT-3724 Phase II studies and our MT-5111...

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.Genocea will highlight GEN-011 as a potential best-in-class adoptive T cell therapy designed to improve upon the current limitations of TIL therapy. Genocea will also outline the robust, scalable manufacturing process – PLANET™ – to simplify and expand cancer patient access to treatment.The event will also feature Eric Tran, Ph.D., Assistant Member at the Earle A. Chiles Research Institute in the...

Firdapse® Q1 2020 Net Revenues of $29.1 MillionFirst Quarter 2020 GAAP Net Income of $10.4 MillionCatalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19 UncertaintiesCatalyst to Host Quarterly Conference Call at 8:30 AM ET TomorrowCORAL GABLES, Fla., May 11, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.“I am very proud of the way that the entire Catalyst team has quickly responded and adapted in these challenging and unprecedented times to ensure the safety of all employees, while still providing...

VANCOUVER, British Columbia, May 11, 2020 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“ALLEGIANT”) (AUAU:  TSX-V) (AUXXF: OTCQX) will be hosting a webcast/conference call on Thursday, May 14 at 11:30 a.m. ET (8:30 a.m. PT) to discuss the state of the junior mining and exploration markets.“Given the recent upswing in the precious metals, there has been a renewed interest in the mining and exploration markets. We are at the very early stage of an emerging bull market in the sector and it is important for investors to get prepared for possibly participating in the next boom cycle,” commented Peter Gianulis, President & CEO of ALLEGIANT.  The call will focus on various aspects of the junior exploration market and will not exceed one hour (including 30 minutes for Q&A).  Topics to be discussed include:Current state of market for...

PRINCETON, N.J., May 11, 2020 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it will participate in two investor conferences in May.On May 12, 2020, Glenn Coleman, chief operating officer will present at the BofA Securities Virtual Health Care Conference at 11:40am ET. On May 20, 2020, Carrie Anderson, chief financial officer will present at the UBS Virtual Global Healthcare Conference.  This presentation will begin at 11:40am ET and will be webcast on the Integra LifeSciences investor relations website at http://investor.integralife.com/events-and-presentations.About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty...

CALGARY, Alberta, May 11, 2020 (GLOBE NEWSWIRE) — Wilmington Capital Management Inc. (“Wilmington”) held its Annual Meeting of Shareholders on May 6, 2020 in Calgary, Alberta and all two nominees proposed for election to the board of directors by holders of Class A Shares and all three nominees proposed for election to the board of directors by the holders of Class B Shares were elected.  Detailed results of the vote for the election of directors are set out below.Management received the following proxies from holders of the Corporation’s Class A and B shareholders in regard to the election of the five directors nominated:Details of votes on all matters of business considered at the meeting are available in the Corporation’s report of voting results filed on SEDAR (www.sedar.com).For further information, please contact:Executive...

Executives to Present Business OverviewsSOUTH ORANGE, NJ, May 11, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nephros, Inc. (Nasdaq: NEPH) announced today that, due to the public health concerns associated with the ongoing coronavirus outbreak and to support the health and well-being of its stockholders, employees, and other partners, the location of the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Nephros, Inc. (the “Company”) has been changed. The Annual Meeting will be held by webcast at virtualshareholdermeeting.com/NEPH2020. Stockholders will not be able to attend the Annual Meeting in person.  The previously announced date and time of the Annual Meeting, which is May 21, 2020 at 9:00 a.m. (Eastern Time) will not change.After the business portion of the Annual Meeting concludes, management will present...

– First Quarter 2020 Consolidated Net Revenue of $444.8 Million –– Completes Sale of Global Marine Group, Reducing Debt –– COVID-19 Business Update –NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, announced today its consolidated results for the first quarter ended March 31, 2020.First Quarter 2020 HighlightsNet Loss attributable to common and participating preferred stockholders of $83.5 million, or $1.82 per share, compared to $1.6 million, or $0.05 per share, in the year-ago quarter.  Net Loss attributable to common and participating preferred stockholders per share for the first quarters 2020 and 2019 includes net loss from discontinued operations of $0.97 per share and $0.09 per share, respectively.Adjusted...

SAN JOSE, Calif., May 11, 2020 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the first quarter ended March 31, 2020.As of March 31, 2020, the Fund’s net assets were approximately $79.8 million, or $11.58 per share, compared with net assets of approximately $127.1 million, or $17.70 per share as of December 31, 2019. As March 31, 2020, the Fund’s portfolio included public and private securities valued at approximately $77.9 million, or $11.30 per share, and approximately $0.05 per share in cash and cash equivalents.Portfolio Summary (as of 3/31/20)During the first quarter of 2020, the Valuation Committee, which was composed of four independent directors, adjusted...